Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer.

"Competing interests: The authors declare the following financial interests/personal relationships, which may be considered potential competing interests. DF has received personal fees from AstraZeneca KK, Boehringer Ingelheim Japan; Ono Pharmaceutical; Bristol-Myers Squibb; Taiho Pharmaceutical; Chugai Pharmaceutical; MSD KK; Eli Lilly Japan KK; Kyowa Kirin; and Novartis Pharma KK, outside of the submitted work. YKitamura is the chief executive officer of N Lab Co., Ltd and its stockholder. JF is an advisor of N Lab Co., Ltd. YS has received personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Novartis, Pizer, Taiho Pharmaceutical, Nippon Kayaku, Bristol-Myers Squibb, Eli Lilly, Takeda, and Kyowa Kirin, outside of the submitted work. TK has received personal fees and scholarship donations from Chugai Pharmaceutical, outside of the submitted work. HM has received personal fees from Chugai Pharmaceutical, outside of the submitted work. TY has received personal fees from Chugai Pharmaceutical, outside of the submitted work. SM has received personal fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Boehringer-Ingelheim Japan, and Takeda Pharmaceutical, outside of the submitted work. AH has received personal fees from Chugai outside of this study, outside of the submitted work. YT has received personal fees from Chugai outside of this study, outside of the submitted work. HT has received personal fees from Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim Japan, and Pfizer Japan, outside of the submitted work. NY has received research funds from Chugai Pharmaceutical, outside of the submitted work."

"Funding: This work was supported by Chugai Pharmaceutical."

"The study was registered in the University Medical Information Network Clinical Trials Registry (UMIN 000039600)."